Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Retatrutide in Hepatic Impairment
NCT05916560Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2023
- Primary completion
- Mar 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of retatrutide in obesity and type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area under the concentration versus time curve from time zero to infinity and Maximum observed concentration. Started Jul 2023; status: completed.
02
Drugs
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05916560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05916560.